Breaking News Instant updates and real-time market news.

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34

Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib

Gilead Sciences (GILD) and Galapagos NV (GLPG) announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20%, 50% and 70% responses, low disease activity and clinical remission at Weeks 12 and 24. Additional FINCH 2 data to be presented include positive results across several patient-reported health-related quality of life measures. Patients receiving filgotinib 100mg or 200mg once-daily experienced greater reduction in the Health Assessment Questionnaire Disability Index at Week 12 compared with those receiving placebo. Patients receiving filgotinib 100mg or 200mg also experienced greater improvements on the Short-Form Health Survey Physical Component Score at Week 12 and on the Functional Assessment of Chronic Illness Therapy-Fatigue Scale at Week 12 compared with patients receiving placebo. Filgotinib demonstrated a safety profile consistent with earlier clinical trials. Rates of serious treatment-emergent adverse events were similar for the filgotinib 100mg, 200mg and placebo groups. The proportion of patients who discontinued study drug due to treatment-emergent adverse events was also similar across groups. Serious infections occurred at similar rates across the three study arms. A total of four cases of uncomplicated Herpes zoster occurred in the filgotinib arms, and one non-serious case of retinal vein occlusion was reported in the filgotinib 200 mg group. Two major adverse cardiovascular events were reported, one in the filgotinib 100mg group and one in the placebo group. No deaths occurred during the study.

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

GILD Gilead
$73.27

-0.9 (-1.21%)

09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
GLPG Galapagos NV
$107.66

2.29 (2.17%)

09/12/18
NOMU
09/12/18
NO CHANGE
Target $124
NOMU
Buy
Galapagos data meets expectations 'and then some,' says Nomura Instinet
Nomura Instinet analyst Christopher Marai says Galapagos NV (GLPG) and Gilead's (GILD) positive top-line results from the Finch-2 study evaluating filgotinib in moderate-to-severe rheumatoid arthritis patients met his expectations "and then some." The anlayst keeps a Buy rating on Galapagos with a $124 price target.
09/12/18
JPMS
09/12/18
INITIATION
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
10/11/18
JEFF
10/11/18
NO CHANGE
Target $210
JEFF
Buy
Jefferies sees shares of Vertex 'going back up and recovering'
Shares of Vertex Pharmaceuticals (VRTX) have pulled back from recent highs of $190-$195 down to $175 on "risk-off rotation" amid the broader market selloff, Jefferies analyst Michael Yee tells investors in a research note. However, nothing fundamental has happened and Vertex still has the "cleanest growth story in large biotech," Yee contends. The triple pill has confirmed Phase III pivotal data coming Q4 and upcoming competitor Galapagos NV (GLPG) data "probably will eventually disappoint," claims the analyst. He also views CTX001 coming off clinical hold as a "nice positive" and thinks the company's pipeline is likely to start garnering more focus over the next 6-12 months. Yee sees the stock "eventually going back up and recovering" and keeps a Buy rating on Vertex with a $210 price target.

TODAY'S FREE FLY STORIES

BLK

BlackRock

$415.08

-1.92 (-0.46%)

, APO

Apollo Global

$27.93

-0.07 (-0.25%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Periodicals
BlackRock, Varde to make rival offers for Banca Carige, Reuters reports »

Varde Partners and…

BLK

BlackRock

$415.08

-1.92 (-0.46%)

APO

Apollo Global

$27.93

-0.07 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

F

Ford

$8.53

0.005 (0.06%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Options
Ford puts lead calls 6:1 »

Ford puts lead calls 6:1.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ASND

Ascendis Pharma

$115.50

-3.71 (-3.11%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Ascendis Pharma announces results of study of hypoparathyroidism at ENDO 2019 »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.31

-2.8 (-1.47%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

IP

International Paper

$44.43

0.03 (0.07%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.74

-2.37 (-1.24%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

14:05
03/25/19
03/25
14:05
03/25/19
14:05
General news
Treasury Action: the $40 B 2-year note sale Tuesday »

Treasury Action: the $40…

AAPL

Apple

$188.48

-2.63 (-1.38%)

, ROKU

Roku

$67.67

4.15 (6.53%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Roku, Amazon.com »

Apple bringing Apple TV…

AAPL

Apple

$188.48

-2.63 (-1.38%)

ROKU

Roku

$67.67

4.15 (6.53%)

AMZN

Amazon.com

$1,762.35

-2.61 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    Jun

AAPL

Apple

$188.51

-2.6 (-1.36%)

, SNE

Sony

$42.00

-0.09 (-0.21%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Sony »

Apple bringing Apple TV…

AAPL

Apple

$188.51

-2.6 (-1.36%)

SNE

Sony

$42.00

-0.09 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

OESX

Orion Energy

$0.91

0.017 (1.90%)

, TM

Toyota

$120.19

0.39 (0.33%)

13:57
03/25/19
03/25
13:57
03/25/19
13:57
Hot Stocks
Orion CEO sees $11M Letter of Intent as 'very significant win' »

In an exclusive interview…

OESX

Orion Energy

$0.91

0.017 (1.90%)

TM

Toyota

$120.19

0.39 (0.33%)

F

Ford

$8.55

0.03 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ANF

Abercrombie & Fitch

$25.25

0.73 (2.98%)

13:55
03/25/19
03/25
13:55
03/25/19
13:55
Options
Abercrombie & Fitch put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:54
03/25/19
03/25
13:54
03/25/19
13:54
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple announces Apple TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:53
03/25/19
03/25
13:53
03/25/19
13:53
Hot Stocks
Apple introduces Apple Arcade game subscription service »

Apple announced Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:51
03/25/19
03/25
13:51
03/25/19
13:51
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade pricing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:50
03/25/19
03/25
13:50
03/25/19
13:50
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.08

-3.03 (-1.59%)

13:48
03/25/19
03/25
13:48
03/25/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:47
03/25/19
03/25
13:47
03/25/19
13:47
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:46
03/25/19
03/25
13:46
03/25/19
13:46
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

RLGY

Realogy

$11.82

0.02 (0.17%)

13:45
03/25/19
03/25
13:45
03/25/19
13:45
Options
Realogy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
03/25/19
03/25
13:45
03/25/19
13:45
General news
Euro$ interest rate futures are cracking higher »

Euro$ interest rate…

AAPL

Apple

$188.55

-2.56 (-1.34%)

, GS

Goldman Sachs

$188.87

0.3 (0.16%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Apple partners with Goldman Sachs, Mastercard to launch Apple Card »

Apple (AAPL) announced…

AAPL

Apple

$188.55

-2.56 (-1.34%)

GS

Goldman Sachs

$188.87

0.3 (0.16%)

MA

MasterCard

$229.47

-1.3 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 15

    Apr

  • 03

    Jun

  • 25

    Jun

AAPL

Apple

$188.55

-2.56 (-1.34%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple aanounces Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

CCL

Carnival

$56.60

-0.13 (-0.23%)

, MKC

McCormick

$142.96

0.66 (0.46%)

13:42
03/25/19
03/25
13:42
03/25/19
13:42
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.60

-0.13 (-0.23%)

MKC

McCormick

$142.96

0.66 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

RHT

Red Hat

$181.76

0.13 (0.07%)

13:42
03/25/19
03/25
13:42
03/25/19
13:42
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.87

-2.24 (-1.17%)

13:40
03/25/19
03/25
13:40
03/25/19
13:40
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.